Pulmonary hypertension associated with left heart disease

European Respiratory Journal, Journal Year: 2024, Volume and Issue: 64(4), P. 2401344 - 2401344

Published: Aug. 29, 2024

Left heart disease (LHD) is the most common cause of pulmonary hypertension (PH), which may be classified further as isolated post-capillary (ipcPH) or combined post- and pre-capillary PH (cpcPH). The 7th World Symposium on Pulmonary Hypertension PH-LHD task force reviewed newly reported randomised clinical trials contemplated novel opportunities for improving outcome. Results from major reinforced prior recommendations against use arterial therapy in outside trials, suggested possible harm. Greater focus phenotyping was viewed one general strategy by to ultimately improve outcomes. This potentially achievable individualising ipcPH

Language: Английский

---

Proteomics of the heart

Physiological Reviews, Journal Year: 2024, Volume and Issue: 104(3), P. 931 - 982

Published: Feb. 1, 2024

Mass spectrometry-based proteomics is a sophisticated identification tool specializing in portraying protein dynamics at molecular level. Proteomics provides biologists with snapshot of context-dependent and proteoform expression, structural conformations, dynamic turnover, protein-protein interactions. Cardiac can offer broader deeper understanding the mechanisms that underscore cardiovascular disease, it foundational to development future therapeutic interventions. This review encapsulates evolution, current technologies, perspectives proteomic-based mass spectrometry as applies study heart. Key technological advancements have allowed researchers proteomes single-cell level employ robot-assisted automation systems for enhanced sample preparation techniques, increase fidelity spectrometers has unambiguous numerous posttranslational modifications. Animal models ranging from early animal experiments heart failure preserved ejection fraction, provided tools challenging organ laboratory. Further will pave way implementation even closer within clinical setting, allowing not only scientists but also patients benefit an interplay relates cardiac disease physiology.

Language: Английский

---

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

Nature Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 17, 2024

Abstract Patients with obesity-related heart failure preserved ejection fraction (HFpEF) display circulatory volume expansion and pressure overload contributing to cardiovascular–kidney end-organ damage. In the SUMMIT trial, patients HFpEF obesity were randomized long-acting glucose-dependent insulinotropic polypeptide receptor glucagon-like peptide-1 agonist tirzepatide ( n = 364, 200 women) or placebo 367, 193 women). As reported separately, decreased cardiovascular death worsening failure. Here, in this mechanistic secondary analysis of treatment at 52 weeks, as compared placebo, reduced systolic blood (estimated difference (ETD) −5 mmHg, 95% confidence interval (CI) −7 −3; P < 0.001), estimated (ETD −0.58 l, CI −0.63 −0.52; 0.001) C-reactive protein levels −37.2%, −45.7 −27.3; 0.001). These changes coupled an increase glomerular filtration rate 2.90 ml min −1 1.73 m −2 yr , 0.94 4.86; 0.004), a decrease urine albumin–creatinine ratio 24 −25.0%, −36 −13%; 0.001; −15%, −28 0.1; 0.051), reduction N-terminal prohormone B-type natriuretic peptide weeks −10.5%, −20.7 1.0%; 0.07) troponin T −10.4%, −16.7 −3.6; 0.003). post hoc exploratory analyses, was significantly correlated pressure, microalbuminuria, improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score increased 6-min walk distance. Moreover, conclusion, volume–pressure systemic inflammation mitigated injury obesity, providing new insights into mechanisms benefit from tirzepatide. ClinicalTrials.gov registration: NCT04847557 .

Language: Английский

---

Heart Failure With Preserved Ejection Fraction in the Elderly Population: Basic Mechanisms and Clinical Considerations

Canadian Journal of Cardiology, Journal Year: 2024, Volume and Issue: 40(8), P. 1424 - 1444

Published: April 10, 2024

---

Chinese guidelines for the diagnosis and management of atrial fibrillation

Pacing and Clinical Electrophysiology, Journal Year: 2024, Volume and Issue: 47(6), P. 714 - 770

Published: April 30, 2024

Abstract Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, significantly impacting patients' quality of life and increasing risk death, stroke, heart failure, dementia. Over past two decades, there have been significant breakthroughs in AF prediction screening, stroke prevention, rhythm control, catheter ablation, integrated management. During this period, scale, quality, experience management China greatly improved, providing a solid foundation for development guidelines diagnosis AF. To further promote standardized management, apply new technologies concepts to clinical practice timely fully, Chinese Society Cardiology Medical Association Heart Rhythm Committee Biomedical Engineering jointly developed Guidelines Diagnosis Management Fibrillation . The comprehensively elaborated on various aspects proposed CHA 2 DS ‑VASc‑60 score based characteristics Asian population. also reevaluated application emphasized significance early highlighted central role ablation control.

Language: Английский

---